ALPINE IMMUNE SCIENCES, INC. Stock: price and insider trades · United States · SEC (Form 4)

About ALPINE IMMUNE SCIENCES, INC.

ALPINE IMMUNE SCIENCES, INC. was a clinical-stage biotechnology company focused on developing innovative protein-based immunotherapies for autoimmune and inflammatory diseases. The company was incorporated in Delaware on December 30, 2014, and built its scientific and operational base in Seattle, Washington, United States. It traded on the NASDAQ under the ticker ALPN before being acquired by Vertex Pharmaceuticals in May 2024. For investors following US-listed healthcare names and SEC Form 4 insider activity, Alpine remained a closely watched biotech story because its valuation was driven primarily by pipeline data rather than commercial sales. Alpine’s business model centered on a protein engineering platform designed to create differentiated immunotherapies that modulate immune signaling pathways. Its lead asset was povetacicept (ALPN-303), a dual antagonist of BAFF and APRIL. The drug was positioned for serious autoimmune diseases, with particular attention on IgA nephropathy (IgAN), a progressive kidney disease with a high unmet need. Company and acquirer disclosures described povetacicept as showing promising, potentially best-in-class clinical activity in IgAN, and the program was viewed as a “pipeline-in-a-product” opportunity because the same mechanism could potentially be extended into other renal autoimmune disorders and immune-mediated conditions. Alpine also had additional programs, including acazicolcept, reflecting a broader platform approach rather than reliance on a single indication. In competitive terms, Alpine occupied a specialized niche within the biotechnology sector: a small, research-intensive company without marketed products, but with a differentiated scientific platform and a lead asset that could meaningfully alter the treatment landscape if late-stage development succeeded. This is the classic high-risk, high-reward biotech profile. The company’s competitive advantage lay in its protein engineering capabilities, its focus on validated immune pathways, and its ability to attract strategic interest from a much larger pharmaceutical acquirer. Like many clinical-stage biotechs, Alpine financed R&D through periodic equity raises and capital markets access, underscoring both the cash-intensive nature of development and the importance of clinical milestones. A defining recent event was Vertex’s April 2024 agreement to acquire Alpine for $65 per share in cash, implying an equity value of roughly $4.9 billion. The deal, approved by both boards, reflected the strategic value of Alpine’s science and the perceived quality of povetacicept’s clinical profile. From a market perspective, this transaction effectively ended Alpine’s standalone public-company story on NASDAQ in the United States, but it also validated the platform and highlighted why the name had attracted significant investor attention: strong science, a lead asset with broad autoimmune potential, and a highly material M&A exit in a competitive biotech landscape.